Sleep quality in patients with non-functioning pituitary adenoma: impact of replacement therapies with an emphasis on the time of hydrocortisone

• Published in: Pituitary 2023-08, Vol.26 (4), p.411-418
• Main Authors: Barlas, Tugba, Yalcin, Mehmet Muhittin, Avci, Doga Ecem, Kaplan, Yigit, Akturk, Mujde, Toruner, Fusun Balos, Karakoc, Ayhan, Altinova, Alev Eroglu
• Format: Article
• Language: English
• Subjects: Adenoma; Adenoma - complications; Adenoma - drug therapy; Adrenal Insufficiency - drug therapy; Diabetes insipidus; Disease management; Endocrinology; Exercise; Human Physiology; Humans; Hydrocortisone; Hydrocortisone - therapeutic use; Insulin-like growth factor I; Insulin-like growth factors; Medicine; Medicine & Public Health; Mental depression; Physical activity; Pituitary; Pituitary Neoplasms - complications; Pituitary Neoplasms - drug therapy; Sleep; Sleep Quality; Steroids; Tumors
• ISSN: 1386-341X; 1573-7403
• DOI: 10.1007/s11102-023-01328-1

Purpose Sleep disturbances are widespread and associated with pituitary diseases, even those under long-term therapeutic management. The aim of this study was to investigate sleep quality in patients with non-functioning pituitary adenoma (NFPA) and determine the factors that might influence sleep quality, including the detailed features of replacement therapy. Methods Eighty-two patients with NFPA and 82 age- and gender-matched control subjects were included. Pittsburgh Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS) and International Physical Activity Questionnaire (IPAQ) were used. Results In the NFPA group, 57.3% of patients had decreased sleep quality, compared to 35.4% in the control group (p=0.005). Although there was no relationship between the presence of hydrocortisone replacement and sleep quality (p>0.05), a strong positive correlation was observed between PSQI and morning hydrocortisone replacement time in patients with secondary adrenal insufficiency (r=0.834, p